Venture Life Group PLC Results of AGM (2378A)

TIDMVLG

RNS Number : 2378A

Venture Life Group PLC

22 May 2023

22 May 2023

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Results of AGM

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, held its Annual General Meeting ("AGM") earlier today at the offices of Simmons & Simmons LLP, CityPoint, 1 Ropemaker St, London EC2Y 9SS.

Ordinary resolutions 1 to 6 were duly passed along with special resolution 8. Special resolution 7 was not passed.

Proxy votes were received in respect of approximately 61% of the Company's issued share capital and the final votes received in respect of each resolution were as follows:

 
          Resolution            Number of    % Votes     Number of        %       Number 
                                 votes for     for      votes against             of votes 
                                                                                  withheld 
 1. To receive and 
  adopt the reports 
  of the Directors and 
  auditor and the audited 
  accounts of the Company 
  for the year ended 
  31 December 2022              77,261,778   99.98%        13,683       0.02%       963 
                               -----------  --------  ---------------  -------  ---------- 
 2. To re-elect as 
  a Director, Gianluca 
  Braguti who seeks 
  re-election                   77,227,821   99.94%        46,239       0.06%      2,364 
                               -----------  --------  ---------------  -------  ---------- 
 3. To re-elect as 
  a Director Jerry Randall 
  who seeks re-election         77,203,609   99.94%        48,239       0.06%     24,576 
                               -----------  --------  ---------------  -------  ---------- 
 4. To appoint Mark 
  Adams as Non-Executive 
  Director                      77,252,547   99.97%        21,513       0.03%      2,364 
                               -----------  --------  ---------------  -------  ---------- 
 5. To appoint Evelyn 
  Partners Limited as 
  the auditor of the 
  Company until conclusion 
  of the next AGM               77,248,712   99.97%        25,749       0.03%      1,963 
                               -----------  --------  ---------------  -------  ---------- 
 6. THAT the Directors 
  are authorised to 
  allot shares in the 
  Company                       57,570,442   74.50%      19,703,618     25.50%     2,364 
                               -----------  --------  ---------------  -------  ---------- 
 7. THAT, if Resolution 
  6 is passed, the Directors 
  are authorised to 
  allot equity securities 
  for cash                      49,242,983   63.73%      28,031,077     36.27%     2,364 
                               -----------  --------  ---------------  -------  ---------- 
 8. The Company is 
  authorised to make 
  one or more market 
  purchases of ordinary 
  shares                        68,942,257   89.22%      8,331,803      10.78%     2,364 
                               -----------  --------  ---------------  -------  ---------- 
 

For further information, please contact:

Venture Life Group PLC [phone]Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cenkos Securities plc (Nomad and Joint Broker) [phone]

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong (Corporate Finance) [phone]

Jonathan Dighe (Sales)

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGNKBBPNBKDCPB

(END) Dow Jones Newswires

May 22, 2023 10:01 ET (14:01 GMT)